Targeted Therapy for Cancer

Edited by Konstantinos N. Syrigos and Kevin Harrington

Targeted therapy offers the prospect of fulfilling the twin goals of maximal therapeutic efficacy with minimal adverse effects
The recent identification of a number of new potential therapeutic targets are covered in this book
Considerable interest in this field of research from both scientists and clinicians
Contributions from a group of international experts
Comprehensive coverage which includes Monoclonal Antibody Targeting Therapy, Combined External Beam Radiotherapy, and Boron Neutron Capture Therapy

Targeted Therapy for Cancer

Edited by Konstantinos N. Syrigos and Kevin Harrington

Description

The quest for therapeutic specificity is implicit in all branches of medicine. In cancer treatment, where the therapeutic modality is a cytotoxic agent such as radiotherapy or chemotherapy, such specificity is of paramount importance. The growing realisation that current therapeutic options are likely to yield no more than incremental improvements in outcome has fuelled the search for more active targeted approaches.

This book discusses the more archetypal systemic targeted therapies, such as those employing monoclonal antibodies or liposomes, but also includes strategies, such as photodynamic therapy and boron neutron capture therapy, that rely on direct physical targeting of disease. The explosion in our understanding of the molecular biology of cancer in recent years has led to the identification of a number of new potential therapeutic targets.

These factors, combined with the likelihood that yet more valuable information will be gleaned from the Human Genome Project, mean that inevitably, significant clinical activity in this arena is anticipated in the coming years with the very real prospect that gene therapy approaches may find an established role in the standard treatment of some of the common cancers.

This book brings together the very latest research in this field from an international group of experts and will prove invaluable for molecular oncologists, cancer researchers and those involved with clinical trials as well as providing a reference for oncologists who are beginning to use some of these therapies in everyday clinical practice.

Targeted Therapy for Cancer

Edited by Konstantinos N. Syrigos and Kevin Harrington

Section I
1:The history of targeted therapy for cancer, Bagshawe
2:Preclinical models for the study of targeted therapy, Rowlinson-Busza
Section II
3:Monoclonal antibody targeting therapy: an overview, Francis & Begent
4:Antibody-directed enzyme prodrug therapy (ADEPT), Syrigos & Harrington
5:Monoclonal antibody targeted radionuclide therapy, Batra, Goel, Pavlinkova & Colcher
6:Combined external beam radiotherapy and radioimmunotherapy, Raben & Buchsbaum
Section III
7:Genetic immunotherapy for cancer, Pandha
8:Targeting of cancer gene therapy, Harrington & Vile
9:Targeted genetic prodrug activation therapy, Rigg & Pandha
10:Antisense therapy as a targeted modality, Waters & Cunningham
11:Dendritic cells-targeting the antitumor immune response, Melcher, Vile, Bateman & Harrington
12:Cell carriers for cancer gene therapy: bridging the gap between targeted vectors and systemic delivery?, Diaz, Chong & Vile
13:Liposomal targeting of cytotoxic drugs, Harrington & Syrigos
14:Targeting blood vessels in vivo by using phage display libraries, Vidal, Cardó-Vila, Lahdenranta, Arap & Pasqualini
Section IV
15:Photodynamic therapy, Hamblin
16:Boron neutron capture therapy: a chemically targeted radiation modality, Morris & Coderre
Section V
17:Cancer immunotherapy directed at growth factor receptors: the ErbB/HER network as a prototype, Sela, Schecheter & Yarden
18:Targeting the metastatic process, Culp, Lin, Kleinman, Kogerman, Judware, Miller & Holleran

Targeted Therapy for Cancer

Edited by Konstantinos N. Syrigos and Kevin Harrington

Author Information

Edited by Konstantinos N. Syrigos, Assistant Professor of Oncology in Medicine, Consultant Medical Oncologist and Head, Oncology Unit, Athens Medical School, Greece, and Kevin Harrington, Molecular Medicine Program, Mayo Clinic, Rochester, USA and Targeted Therapy Laboratory, Institute of Cancer Research, London

Contributors:

Wadih Arap, Department of Genitourinary Medical Oncology and Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, USA

K. D. Bagshawe, CBE, Emeritus Professor of Medical Oncology, Imperial College of Science and Medicine, London, UK

Surinder K. Batra, Associate Professor, Department of Biochemistry and Molecular Biology, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA

Andrew Bateman, Molecular Medicine Program, Mayo Clinic, Rochester, USA

Richard H. J. Begent, Professor of Medical Oncology, Cancer Research Campaign Targeting and Imaging Group, Department of Oncology, Royal Free and University College Medical School, London, UK

Donald J. Buchsbaum, Professor and Director, Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham, USA

Marina Cardó-Vila, Department of Genitourinary Medical Oncology and Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, USA

Heung Chong, Molecular Medicine Program, Mayo Clinic, Rochester, USA

Jeffrey A. Coderre, Medical Department, Brookhaven National Laboratory, New York, USA

David Colcher, Director, Radioimmunotherapy Research, Coulter Pharmaceutical, San Francisco, USA

Lloyd A. Culp, Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, USA

David Cunningham, Head of Gastrointestinal and Lymphoma Units, Royal Marsden Hospital, Sutton, UK

Rosa Maria Diaz, Molecular Medicine Program, Mayo Clinic, Rochester, USA

Roslyn J. Francis, Cancer Research Campaign Targeting and Imaging Group, Department of Oncology, Royal Free and University College Medical School, London, UK

Apollina Goel, Research Associate, Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, USA

Michael R. Hamblin, Assistant Professor of Dermatology, Harvard Medical School, Massachusetts General Hospital, Boston, USA

Kevin J. Harrington, Melucular Medicine Program, Mayo Clinic, Rochester, USA

Julianne L. Holleran, Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, USA

Raymond Judware, Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, USA

Nanette R. Kleinman, Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, USA

Priitt Kogerman, Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, USA

Johanna Lahdenranta, Department of Genitourinary Medical Oncology and Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, USA

Wen-Chang Lin, Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, USA

Alan Melcher, Molecular Medicine Program, Mayo Clinic, Rochester, USA

Carson J. Miller, Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, USA

Gerard M. Morris, Research Institute, University of Oxford, UK

Hardev S. Pandha, Honorary Simon Weinstock Senior Lecturer in Tumor Immunology, Department of Medical Oncology, St George's Hospital Medical School, London, UK

Renata Pasqualini, Department of Genitourinary Medical Oncology and Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, USA

Gabriela Pavlinkova, Instructor, Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, USA

David Raben, Assistant Professor, Department of Radiation Oncology, University of Colorado, Denver, USA

Anne Rigg, Department of Medicine, Royal Marsden Hospital, London, UK

G. Rowlinson-Busza, Antisoma Research Ltd, St George's Hospital Medical School, London, UK

Bilha Schecheter, Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel

Michael Sela, Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel

K. N. Syrigos, Consultant Medical Oncologist, Head, Oncology Unit, Athens Medical School, Sotiria General Hospital, Athens, Greece

Yosef Yarden, Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel

Claudia Vidal, Department of Genitourinary Medical Oncology and Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, USA

Richard G. Vile, Melucular Medicine Program, Mayo Clinic, Rochester, USA

Justin Waters, Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK

Targeted Therapy for Cancer

Edited by Konstantinos N. Syrigos and Kevin Harrington

Reviews and Awards

"Targeted Therapy for Cancer brings together the very latest research in this field from an international group of experts and will prove invaluable for molecular oncologists, cancer researchers and those involved with clinical trials, as well as providing a reference for oncologists who are beginning to use some of these therapies in everyday clinical practice." - Anticancer Research 23